OM1’s 650,000-Patient Real-World Submission Shows Evidence Generation Is Becoming an AI Problem Too
OM1 supported a regulatory submission for Hologic’s Aptima HPV assay using real-world data from 650,000 patients, highlighting the scale now required to make a persuasive evidence case. The submission reflects a growing trend in which data infrastructure and analytics are becoming central to regulatory strategy.
This submission is a reminder that modern regulatory wins are increasingly built on data scale, not just bench performance or traditional clinical trial design. A real-world dataset of 650,000 patients is a substantial signal that evidence generation is moving deeper into longitudinal, population-level analytics.
The interesting angle is that companies like OM1 are becoming critical middle layers between manufacturers and regulators. They are not just collecting data; they are shaping the evidentiary narrative that can support approval, label expansion, or clinical confidence.
That has implications for the diagnostics market. As payers and regulators place more weight on real-world evidence, the winners may be those with the strongest ability to assemble credible patient-level data, clean it, and translate it into a submission-ready argument.
It also raises the bar for quality. Large datasets are not automatically persuasive if they are biased, incomplete, or poorly contextualized. The strategic challenge is no longer simply having data, but proving that the dataset is representative and analytically defensible enough to stand up in a regulatory review.